Descotes J
Drug Metab Rev. 1985;16(1-2):175-84. doi: 10.3109/03602538508991434.
Immunomodulating agents are increasingly used in clinical practice to alter the course of various malignancies, autoimmune diseases, or immunodeficiencies. Experimental data obtained in laboratory animals suggest that nearly all agents available today are likely to inhibit hepatic drug-metabolizing enzymes. Although further investigation is warranted, a direct stimulation of the reticuloendothelial system is likely to play a key role. Potentially severe drug interactions are the main clinical consequences to be considered, particularly in the field of cancer chemoimmunotherapy and vaccination. Besides immunomodulating agents, drugs with the toxic potential for immunoenhancement may also be considered in that respect.
免疫调节剂在临床实践中越来越多地用于改变各种恶性肿瘤、自身免疫性疾病或免疫缺陷的病程。在实验动物身上获得的实验数据表明，如今几乎所有可用的药物都可能抑制肝脏药物代谢酶。尽管有必要进一步研究，但网状内皮系统的直接刺激可能起关键作用。潜在的严重药物相互作用是需要考虑的主要临床后果，尤其是在癌症化学免疫疗法和疫苗接种领域。除免疫调节剂外，在这方面也可考虑具有免疫增强毒性潜力的药物。
